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Beta 2 nficroglobulin isoforms in healthy individuals and in amyloid
deposits. Beta 2 microglobulin (2m) is classically known to have isoforms
with isnelectric points (p1) 5.7 and 5.3. New isoforms of /32m with lower p1,
probably due to modifications with advanced glycation end products, were
found in the amyloid deposits of dialysis related amyloidosis (DRA), and
they were proposed as the amyloidogenic forms of f32m. The other
modifications in f32m from amyloid deposits are partial proteolysis and
single amino acid replacement (Asn by Asp at position 17). However,
there are no data on the sequence of the different isoforms of 132m from
amyloid deposits. Amyloid deposits surgically obtained from the carpal
tunnel from 13 dialysis treated patients and urine from 10 healthy
volunteers and 5 living-related kidney donors were analyzed for f32m
content. Two-dimensional gel electrophoresis (2D-PAGE) of 2m from
amyloid deposits showed the presence of four or more isoforms with pls
<5.7. All the spots migrating at 12 kDa Mr region and between 4 and 6
pH reacted with rabbit anti-human f32m antibody by Western blotting,
confirming that they were p2m isoforms. /32m isoforms from the amyloid
deposits were then separately purified with an IEF column (PB94,
Pharmacia@) for analysis. Enough quantities of three pure j32m isoforms
could be obtained in two cases. The sequence analysis showed an intact
N-terminus in all the isoforms. There was Asn in the 17th residue in all the
isoforms sequenced. 2D-PAGE of urine from 8 out of the 10 healthy
volunteers showed the presence of j32m. In two of them J32m also displayed
four different isoforms. At least four isoforms were observed in urine of all
the kidney donors. The present study shows that the elution peaks of three
different f32m isoforms in gel isoelectrofocusing contain 132m with intact
N-terminus. None of them have deamidated their 17th residue, More
importantly, the j32m isoforms with lower p1 are not specific for amyloid-
osis as they were found in urine from kidney donors and in normal
volunteers. These results bring into question the hypothesis that dialysis
related amyloidosis is due to the known modifications on j32m. They
suggest that the precipitation of f32m into amyloid fibrils should result
from the interaction of 132m with other factors with amyloid enhancing
activity.
Dialysis related amyloidosis (DRA) is a well known complica-
tion of renal failure frequently presenting with carpal tunnel
syndrome, bone cysts, pathological fractures and scapulohumeral
periarthritis [1]. It is mainly observed in long-term dialysis survi-
vors and it was first described by the group of Tassin in France [2,
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3]. In 1985 Gejyo et al identified the main protein constituent as
being beta 2 microglobulin (2m) [4], and suggested that the
protracted increase in serum levels of f32m would result in the
formation and deposition of amyloid fibrils [4]. However, soon
after Gejyo's report, it was observed that the serum levels of 2m
did not reflect the DRA risk [5]. Subsequently, several studies
have confirmed similar serum levels of !32m in hemodialysis
patients having or not having DRA [6—11]. Therefore, the pro-
tracted increase in serum level of f32m is not the only prerequisite
for amyloid fibril formation.
Attempting to understand the reasons by which J32m precipi-
tates into amyloid fibrils, a few different groups have analyzed the
biochemical properties and sequence of the /32m present in the
amyloid deposits [12—15]. From the studies of Hall, Ricanati and
Vacca in 1977 [16], it was accepted that J32m normally presents
with two different isoforms with calculated pls of 5.7 and 5.3,
respectively. The earliest studies of the f32m from amyloid depos-
its showed that the f32m consisted of these two known isoforms, as
well as at least two extra isoforms with a more acidic p1 [12, 13].
It was suggested that these new isoforms would be specific for
amyloid [12]. Linke et al [14] found that the N terminal side of the
2m obtained from the deposits was almost constantly proteo-
lyzed after a lysine amino acid [14], and these authors suggested
that partial proteolysis facilitates the appearance of amyloid fibrils
[14]. Odani et al [15] reported the replacement of Asn by Asp at
the 17th amino acid of a novel isoform of /32m that had been
previously proposed as specific for DRA [17]. Vesy recently,
Miyata et al [181 have shown that the more acidic isoforms of 132m
are modified with advanced glycation end products [181. However,
the sequence analysis of the more acidic isoforms of 132m has not
been reported previously.
In the present study we aimed to characterize 2m from
amyloid deposits as well as from urine of normal volunteers to
assess the specificity of the new 2m isoforms in regards to DRA.
Further, we aimed to separate and purify the different isoforms of
132m to perform differential sequence analysis. This was designed
in order to assess whether the new more acidic isoforms of f32m
corresponded to the proteolyzed f32m reported by Linke et al [14],
and/or they were deamidated in the 17th amino acid, as reported
by Odani et al [15]. A positive result would have conciliated the
different findings reported on the biochemical structure of the
amyloidogenic /32m.
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Table 1. Characteristics of the patients included in the study
Group Description N (sex) Age Sample
DRA 32-microglobulin
amyloidosis
13 (4F/9M) 57 3 Amyloid
deposits
Control I Healthy volunteers 10 (3F/7M) 34 5 Urine
Control II Kidney donors 5 (3F/2M) 47 7 Urine
Methods
Patients and control group
The characteristics of the individuals included in the study are
described in Table 1.
Group I. Thirteen hemodialysis patients previously operated on
for carpal tunnel syndrome, who were histologically diagnosed
with amyloid deposits, were included in this study. All the
materials surgically removed were retained for analysis.
Group II. Ten healthy persons agreed to collect urine and be
included in the study as normal controls. They were three females
and seven males, 34 5 years old with normal renal function (81
9 .tmol/liter serum creatinine), normal blood pressure (average
values 116/67 mm Hg), and who were receiving no pharmacolog-
ical treatment. Their protein excretion was measured by the
Bradford's method as modified by Spector [19] and found to be
105 10 mg/day.
Group III. Five living-related kidney donors provided their
urine for analysis before and immediately after kidney donation,
while in the hospital. They obviously had normal renal function,
no proteinuria, and they were normotensive before surgery. Their
glomerular filtration rate by one week after kidney donation was
63 10% of the value before surgery.
Protein extraction
From urine. The collected urine was ultrafiltered to concentrate
the proteins using a 5 kDa cut-off membrane as described
elsewhere [20]. After removing the salts by dialysis the protein
solutions were freeze dried and stored at —20°C until analyzed.
From the amyloid deposits. Proteins were obtained from the
surgically removed amyloid deposits following a modification of
Gorevic et al's method [12] as previously described [21]. Briefly,
after three freeze-thaw cycles the deposits were homogenized with
a Polytron (Kinematica GmbH, Luzerne, Switzerland) in 0.1
mol/liter phosphate buffered saline (PBS) and centrifuged at
13000 rpm for 30 minutes at 4°C in a Sorvall RC-5B centrifuge.
This step was repeated discarding the supernatant until it was free
of protein (Bradford assay, Bio-Rad reagents). The pellet was
re-homogenized in 6 mol/liter guanidine HC1 and left overnight at
4°C. The supernatant was removed, dialyzed against deionized
water (MilliQ, Millipore, MN, USA) and freeze-dried.
Two dimensional polyaciylamide gel electrophoresis (2D-PAGE)
2D-PAGE was performed according to O'Farrell's method [22],
modified as previously reported [23]. In brief, between 350 and
400 tg of proteins were solubilized in 9.5 M urea, 10% Nonidet
NP4O, 0.1 mrvi dithiothreitol (DTI) and an ampholine mixture
with a pH range from 2 to 10. The isoelectrofocused proteins were
then separated in 5 to 20% gradient SDS-PAGE. The markers of
molecular weight run with the proteins were a-lactalbumin (14
kDa), soybean trypsin inhibitor (20 kDa), carbonic anhydrase (30
kDa), ovalbumin (40 kDa), bovine serum albumin (67 kDa) and
phosphorylase b (94 kDa). Gels were stained with Coomassie
blue.
Western blotting
Proteins were transferred from the SDS-PAGE to nitrocellu-
lose sheets in the presence of 0.2% SDS, as previously described
[23], based on Burnette's technique [24]. Polyclonal rabbit anti-
human /32m antibody (BlO-YEDA Laboratories, Rehovot, Israel)
was used as the first antibody, and goat anti-rabbit antibodies
conjugated with immunoperoxidase were used to screen for the
presence of antigen-antibody complexes.
132-microglobulin purification
132m purification and isoform separation from the proteins
obtained from the amyloid deposits was performed according to
the method of Nissen, Thim and Christensen [25] and modified as
previously reported [26]. The proteins were resuspended in 25 mrvi
imidazole-HCI pH 7.41 buffer and run through a G75 sephadex
100 X 4 cm column with the same buffer. The tubes containing
2m were pooled and freeze-dried. The protein was resuspended
in imidazole buffer and run through a Polybuffer Exchanger 94
(Pharmacia Fine Chemicals, Uppsala, Sweden) 60 X 1.5 cm
column equilibrated with imidazole buffer and eluted with 1:8
Polybuffer 74 HC1 pH 4, to separate the isoforms. The f32m
isoforms were then separately run through a C14 column by
reverse HPLC to remove the Polybuffer 74, using standard
methods. The purity of the protein preparations was assessed by
15% SDS-PAGE according to Laemmli [27].
Sequence studies
The N-terminal amino acid sequence was determined by Ed-
man degradation using a gas phase microsequencer 470A on line
coupled to a 120H PTH analyzer (Applied Biosystems, Foster
City, CA, USA), both operated according to the manufacturer's
recommendations.
Results
Protein identification from amyloid deposits and from urine.
2D-PAGE of the proteins extracted from the amyloid deposits
displayed the presence of several spots at the 12 kDa region.
These spots migrated at regions with pH ranging from 5.7 to 4.
Three examples of the heterogeneity of f32m are shown in Figure
1, a, b, and c. Western blotting using anti-132m antibody showed a
positive reaction with all the spots at this molecular weight (12
kDa), suggesting that they were different isoforms of 132m (Fig. 2).
Fig. 1. Two-dimensional sodium dodecyl sulfate polyactylamide gel electrophoresis of /32-microglobulin. The proteins run in the gel were obtained from
amyloid deposits (a, b and c), urine from normal volunteers (d, e and f) or urine from kidney donors after surgery (g, h and 1). Note that 132m displayed
four isoforms in all the amyloid deposits (in brackets). In the examples selected for the normal volunteers, there is no j32m observed in the case d, while
there was two isoforms in case e (arrow), and four isoforms in case f (in brackets). It is also noteworthy that all the kidney donors had four or more
isoforms of f32m (in brackets in the examples g, h and i). The molecular weight markers are as described in the Methods section.
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Fig. 2. Western blotting of f32-microglobulin from
amyloid deposits. f32m was transferred after
migration in 2D-PAGE to a nitrocellulose sheet
and incubated with anti-/32m antibody. Over six
spots in the 12 kD region specifically reacted
with the antibody, suggesting a high
heterogeneity for /32m. Note that in this case no
positive spots were observed in the 20 to 30
kDa molecular wt range, indicating that there
was no cross reaction with other proteins
present in this molecular wt range and that no
dimers were present in this protein preparation.
Fig. 3. /32-microglobulin purification from
amyloid deposits. Resuspended proteins were
loaded onto the sephadex G75 column and run
with imidazole buffer (Methods). The elution
pattern at 280 nm is given and the control SDS-
PAGE is shown in the inset (external lanes
correspond to standards: 14, 20, 30, 40, 68, 95
kDa). The first peak contained a mixture of
high molecular weight proteins; the second
peak contained almost uniquely 2m and the
third peak was salts only.
/32m could be observed in Coomassie blue stained 2D-PAGE of
urinary proteins from 8 out of the 10 normal volunteers of group
II. In two of them, the 12 kDa spots were arranged in an identical
manner to the f32m observed in the proteins obtained from the
amyloid deposits. Three different examples of urinary proteins
from the control group are shown in Figure 1, d, e and f.
At least four isoforms of /32m were observed in all the kidney
donors studied after nephrectomy (Fig. 1, g, h, i).
/32m purification from amyloid deposits. Gel filtration of the
proteins obtained from the amyloid deposits in the sephadex G75
column resulted in three different peaks (Fig. 3). SDS-PAGE of the
pooled tubes of each peak showed the presence of high molecular
weight proteins in the first peak and no protein in the third one. f32m
was eluted almost purely in the second peak (Fig. 3, inset).
Gel isoelectrofocusing in the Polybuffer exchanger 94 column of
the pooled 2m showed three different peaks between the elution
tube numbers 70 and 110 (Fig. 4). The measured pH gave a
calculated p1 for these three isoforms of 6.1, 5.75 and 5.5.
SDS-PAGE of the three different peaks showed the presence of a
single band migrating just under 14 kD (Fig. 4, inset).
Sequence analysis of the different f32m isoforms. Sequence anal-
ysis of the 20 first amino acids of the three purified proteins from
the first patient showed identical results. The sequences obtained
were identical to the known N-terminal sequence of human 132m
[28] (Table 2). Similarly, the analysis of the three isoforms purified
from the amyloid deposit of the second patient showed the
presence of N-terminus intact 2m and Asn in the 17th amino acid
without deamidation. However, this second sequence analysis
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Fig. 4. Isoform separation in polybuffer exchanger
94 (PB94) column. Lyophilyzed proteins from the
pooled j32m containing peak were run through
the column after resuspending in imidazole buffer
as described in the Methods section. The elution
pattern at 280 nm displayed three different peaks
between tube numbers 70 and 110. The control
SDS-PAGE of the peaks a, b, and c is shown in
the inset (external lanes correspond to standards:
14, 20, 30, 40, 68, 95 kDa). The three peaks
contained pure /32m.
Table 2. Sequence analysis of the different p2-microglobulin isoforms
purified from the amyloid deposit
Ile-Gln-Arg-Thr-Pro-Lys-Ile-Gln-Val-Tyr-Ser-Arg-His-Pro-Ala-Glu-Asn-
Gly-Lys
Ile-Gln-Arg-Thr-Pro-Lys-Ile-Gln-Val-Tyr-Ser-Arg-His-Pro-Ala-Glu-Asn-
Gly-Lys
Ile-Gln-Arg-Thr-Pro-Lys-Ile-Gln-Val-Tyr-Ser-Arg-His-Pro-Ala-Glu-Asn-
Gly-Lys
The three of them had an identical N-terminus sequence, which is given.
displayed a higher background coming from peptides which
co-purified with f32m and whose identity could not be ascertained.
Discussion
DRA, like the other types of amyloidosis, has an unknown
pathophysiology. To understand the mechanisms of formation of
amyloid fibrils, it appears wise to first study the most prominent
protein component of the deposits. Therefore, modifications of
132m obtained from amyloid deposits, when compared to known
132m, were suspected of having a role as amyloid inducers.
The controversy remains as to whether proteolysis of 132m is
required to precipitate into amyloid fibrils. Proteolyzed forms of
f32m have been found in the amyloid deposits, mainly associated
with intact f32m in over 12 reported cases [14]. However, Gorevic
et al [121 reported the complete sequence of the 132m purified
from the amyloid deposits and found it to match perfectly with the
known one for J32m [281. Other groups [4, 15, 23, 29] and our
present data suggest that proteolysis is at least not constant, and
therefore it would not be a prerequisite for amyloid formation.
From the vecy first studies of f32m from dialysis-related amyloid
deposits, it was observed that 132m consisted of four or more
isoforms [12, 13] while the normal 132m was reported to have only
two different isoforms with pls 5.7 and 5.3, respectively [16]. On
these grounds, it was proposed that the more acidic isoforms
would be the amyloidogenic /32m [12]. A single study has reported
the sequence analysis separately of two isoforms of 132m: the 5.7
and a second one which was named novel 132m with 5.22 p1 [15].
They found a single amino acid replacement in the 5.22 p1
isoform, a deamidation in the 17th residue [15]. Our present
investigation represents the first report of the individualized
N-terminal sequence of three 132m isoforms from amyloid depos-
its, including one with lower p1. The three isoforms sequenced had
no proteolysis nor deamidation of the 17th Asn. Although our
data do not exclude proteolysis or deamidation for the most acidic
f32m isoforms, they show that these modifications are not required
to obtain f32m with p1 lower than the two previously reported as
normal ones.
Very recently, Miyata et al have elegantly shown that the more
acidic isoforms are modified with advanced glycation end prod-
ucts and this modifications would suffice to decrease their p1 [18].
However, although the modifications described by Miyata et al
provide an explanation for 132m polymorphism [18], the specificity
of the more acidic isoforms in inducing amyloidosis deserved to be
assessed further. Actually, some recent data suggest that they may
not be specific for DRA and dialysis patients [26, 30]. Vincent et
al [30] have reported the presence of more acidic isoforms in
normal blood donors (no renal failure or amyloidosis) [30], and
we have identified more than four isoforms in the serum of a
dialyzed patient without DRA [26]. In the present study we
decided to include a greater number of volunteers in the control
group (up to 10) and we also added a second control group
consisting of five kidney donors. Given the known variability of
f32m in final urine we could expect some variability in the presence
of /32m in normal individuals. This was the case as 2 out of the 10
normal individuals studied had no evident 132m in urine and 6 had
/32m with the two classically reported isoforms. Interestingly, the
remaining 2 normal volunteers as well as all the uninephrecto-
mized kidney donors, had four isoforms of f32m in their urine.
Therefore, the more acidic isoforms of /32m are clearly not specific
for DRA.
If the presence of more acidic 132m isoforms is not the raison
d' être for the appearance of amyloidosis, whether they are
proteolyzed or unproteolyzed, deamidated or modified with the
end glycation products, becames not as relevant as it has been
thought to the present. Thus, we should also look at other putative
amyloid enhancing factors. A similar trend in the orientation of
research in another type of amyloidosis, Alzheimer's disease, has
been observed in recent years. The major protein component was
identified as 13-protein which is a product from a membranous
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protein [A4 precursor protein (APP)] identified in 1987 [31].
From the first reports it was suggested that an abnormal process-
ing of this membranous protein would result in this pathological
peptide with amyloidogenic properties [31J. However, recently it
has been shown that normal cells are also able to encode and
synthesize n-protein [32, 33]. This, associated with the lack of
increase in serum levels of the APP in Alzheimer's disease
patients [34], led to the conclusion that additional factors, other
than those linked to the structure and level of APP must account
for amyloid deposition [34]. Some recent data showing the
coexistence of several amyloidogeneic proteins in a single amyloid
type suggest that these other factors may be at the origin of
amyloid deposit formation and that the fibrillar proteins would
have a more passive role acting as a substrate [35—37]. The target
of the studies on the pathophysiology of Alzheimer's disease has
been broadened to other associated factors, among which note-
worthy is the identification of the antiprotease nexin II [38—41].
Antiproteases have also been proposed to participate in the
genesis and/or maintenance of amyloid deposits in DRA [42]. We
identified s2-macroglobulin in the deposits of DRA patients [21]
and its presence along with other antiproteases has been con-
firmed by Campistol et al [43]. Although some recent clinical data
are in keeping with a possible participation of a2-macroglobulin
in DRA [10], this hypothesis still needs confirmation. The other
compounds identified in the deposits of DRA, such as amyloid P
substance and glucosaminoglycans [44], and JUNO protein [45]
also deserve further analysis.
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